Search research articles
Contact Us
Filters
Showing results (1201-1210 of 1,257) with videos related to
Page
of 126
Sort By:
Lancet (London, England)
|
September 2, 2024
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
Mikhail N Kosiborod, John Deanfield, Richard Pratley, et al.
The American Journal of Cardiology
|
April 28, 2004
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)
A Michael Lincoff, John A Bittl, Neal S Kleiman, et al.
JAMA
|
April 5, 2008
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial
Steven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
JAMA Cardiology
|
May 16, 2021
Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial
Steven E Nissen, A Michael Lincoff, Kathy Wolski, et al.
American Heart Journal
|
August 17, 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library
John L Petersen, Kenneth W Mahaffey, Richard C Becker, et al.
European Heart Journal Open
|
August 4, 2022
Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation
Paul C Cremer, Calvin C Sheng, Debasis Sahoo, et al.
Journal of the American College of Cardiology
|
September 1, 2024
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial
Benjamin M Scirica, A Michael Lincoff, Ildiko Lingvay, et al.
Lancet (London, England)
|
August 24, 2024
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
John Deanfield, Subodh Verma, Benjamin M Scirica, et al.
Diabetes & Vascular Disease Research
|
October 21, 2017
Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes
Stefano Savonitto, Nuccia Morici, Anna Nozza, et al.
American Heart Journal
|
September 27, 2023
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics
Stephen J Nicholls, Deepak L Bhatt, John B Buse, et al.
Page
of 126
Search research articles
Search
Showing results (1201-1210 of 1,257) with videos related to
Sort By:
Page
of 126
Lancet (London, England)
|
September 2, 2024
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
Mikhail N Kosiborod, John Deanfield, Richard Pratley, et al.
The American Journal of Cardiology
|
April 28, 2004
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)
A Michael Lincoff, John A Bittl, Neal S Kleiman, et al.
JAMA
|
April 5, 2008
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial
Steven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
JAMA Cardiology
|
May 16, 2021
Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial
Steven E Nissen, A Michael Lincoff, Kathy Wolski, et al.
American Heart Journal
|
August 17, 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library
John L Petersen, Kenneth W Mahaffey, Richard C Becker, et al.
European Heart Journal Open
|
August 4, 2022
Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation
Paul C Cremer, Calvin C Sheng, Debasis Sahoo, et al.
Journal of the American College of Cardiology
|
September 1, 2024
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial
Benjamin M Scirica, A Michael Lincoff, Ildiko Lingvay, et al.
Lancet (London, England)
|
August 24, 2024
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
John Deanfield, Subodh Verma, Benjamin M Scirica, et al.
Diabetes & Vascular Disease Research
|
October 21, 2017
Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes
Stefano Savonitto, Nuccia Morici, Anna Nozza, et al.
American Heart Journal
|
September 27, 2023
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics
Stephen J Nicholls, Deepak L Bhatt, John B Buse, et al.
Page
of 126